💡 Want to know why Ireland is one of the leading locations for Life Sciences? 👇 Find out more about Ireland's position and offering in the competitive landscape with this concise article.....well worth a quick read!
Team Horizon’s Post
More Relevant Posts
-
Endocannabinoid Pharmacology Expert | Queer, Neurodivergent, Stoner Scientist
Yesterday we got confirmation that The Network of Applied Pharmacognosy officially submitted its first grant to the National Institute of Health - the largest funding source for our level of biochemical research, a category called “basic science.” The standard process of obtaining funding for the basic sciences is extreme, it requires a huge amount of administrative support, and we are fortunate to have a first-of-its-kind collaboration with an academic partner, the Makriyannis Lab where I did my PhD. This is the first of many academic grants that we hope to put in this year in collaboration with industrial research teams who are at the cutting-edge of their specialties with unique prior knowledge. We have some interesting preliminary data on chemodiverse interactions with CBG... My PhD mentor Dr. Alexandros Makriyannis established many of the first research cannabinoids used as tools to study and understand targets in the endocannabinoid system, including the CB1 and CB2 receptors. He also did research on how the cannabinoids change the membrane of a cell, and, therefore, affect all receptor signaling in a non-specific manner. During my PhD, my colleague was responsible for “growing” the CB1 receptor constructs that were in the first crystal structures. Regardless of whether we get the grant or not (the chances are always extremely slim and the competition for this one will absolutely be stiff), our perspective has been formally submitted to the NIH. Dr. Riley D. Kirk, PhD and I are radicals, and the submission of a radical opinion in a grant of this size is an accomplishment on its own to me. Here is a quote from the application: "Academic research must keep pace with practices being presented in the real world as the cannabis industry continues to expand and diversify. The importance of reducing barriers to entry in cannabis science becomes increasingly urgent, underscoring the critical role that collaborative efforts between industrial and academic researchers will play in advancing the field and promoting public health. " A huge shoutout to our key contributors to this first grant: Vicente LLP, Institute of Cannabis Science, and CSQ Cannabis Safety & Quality I've never been so proud of my research and my work. Thank you #cannabiscommunity
-
Partnering with Key Pharma and Biotech clients on clinical development of their pipeline
Happy New Year, everyone! 🎉 Fortrea is excited to kick off 2025 in the UK with a free symposium focused on early phase clinical trials. Join us in Cambridge on the 30th of January and in Oxford on the 4th of February. Here's a sneak peek at our agenda and speakers: - Jim Bush: Addressing Complexity in Early Phase Clinical Trials - Paul Baldrick: Toxicology-Clinical Translation: Using Nonclinical Data To Support Safe Clinical Trials - Heather Saywell: Addressing sustainability in a new world-class CRU: doing the right thing - Catherine Laing: hAME studies – How the FDA Guidance aligns with recent trends Hurry! Spaces are limited, so secure your spot now: - Cambridge: Babraham Research Institute on the 30th of January. Register here: [link] - Oxford: Oxford Science Park on the 4th of February. Register here: [link] Join us for insightful discussions and networking opportunities. See you there! #Fortrea #Clinicaltrials #PhaseI #Sustainability #hAME
-
Dr. Sinéad Keogh, from BioPharmaChem Ireland has strongly advocated for a national life sciences strategy led by Ireland's Department of Enterprise, Trade and Employment. In interviews and public discussions, she has highlighted the critical role of life sciences in Ireland’s economy and its significant global impact, emphasizing the sector’s contributions during the pandemic and its ability to drive innovation and economic growth. Read the interview here. https://lnkd.in/e7Me3DYc
-
Stacie Bell, PhD, Executive Vice President of #LupusTherapeutics, the clinical research affiliate of the LRA, is enthused to attend today's Clinical Trials Day hosted by Endpoints News, the preeminent international biopharma news outlet. The event is exploring the latest trends in clinical research and how companies are designing better clinical trials to optimize outcomes. #lupusclinicalresearch #lupusclinicaltrials #lupusresearch
-
-
check this article from Gary Quashie
ℹ Comparing the US & Europe Clinical Trial Landscapes ℹ Ahead of next week's COG New England, I sat down with Gary Quashie, of OPIS to discuss the challenges faced by #biopharma trial sponsors, as well as drawing comparisons from the European environment for #clinicaltrials. Key highlights from our discussion included: 👉 Patient-centric trials have shown faster enrolment and initiation, emphasising the importance of including #patientadvocacy groups and CROs early in #protocoldevelopment 👉 The US remains the top location for #clinicalresearch due to the FDA's robust framework, NIH support, renowned medical institutes, and a large, diverse patient population 👉 The number of US trials are declining, China has seen a steady increase in recent years, though political impact is yet to be seen 👉 Europe can be faster and more cost-effective for running studies, with strong Key Opinion Leader advocates and the streamlined European Clinical Trials Information System (#CTIS) regulatory process 👉 Sponsors should partner with experienced CROs, leverage patient diversity plans, carefully assess #sitefeasibility, and embrace #patientcentric approaches and emerging technologies to navigate the evolving clinical trials landscape Read in full below 👇 & meet Gary at COG New England next week!
-
It is time to get together to discuss the future challenges and opportunities for European clinical research …. there has never been a better time .... There has never been a better time to bring together the stakeholders to explore the present and future of clinical research in Europe. There are many challenges and opportunities ahead and many of these require a collaborative approach. The Annual EUCROF Conference will bring together pharma, biotech, regulators, CROs, technology providers, academic institutions, and patients, to provide their perspectives on a wide range of clinical research subjects. More than 50 speakers, over 35 exhibiting companies, along with attendees from more than 175 different organisations, will be joining us in Copenhagen from 2-4 February for EUCROF25. Register for EUCROF25 now: https://lnkd.in/e8bt2cqG EUCROF25 Premier Sponsors: Curewiki, EvidentIQ, Medidata Solutions, Nubilaria - Your data specialists, ICON plc Dr. Martine Dehlinger-Kremer, Simon Lee, Martin O'Kane, Sverre Bengtsson, Benedikt Van Nieuwenhove, Alexandre Malouvier, Antonio Torres, Nicole Bohrmann, Cristina Florescu Moraid, Alan Yeomans, Nira Garty #clinicalresearch #clinicaltrials #clinicaloperations #gcp #EUCROF #EUCROF25
-
An important program supporting and leading to careers in an in-demand field.
Hello Everyone If you are/know anyone who is an internationally trained healthcare/medical professional looking to get that additional Canadian education to get into the pharmaceutical/Clinical Research field, direct them to our Clinical Research Program at York University School of Continuing Studies! Our team of instructors are current practitioners in the industry ranging from Senior Managers to Directors at places like Princess Margaret Cancer, Janssen Inc., The University Health Network, Mount Sinai Hospital, and Hoffman Laroche. We have a unique blended in-person offering starting this month, so if you are interested, don't let this opportunity pass you by! Please repost, and spread the word!
